TheEdgeResearch
Home / Stocks / SPHRF

Starpharma Holdings Limited (SPHRF)

OTC Healthcare Biotechnology
$0.32 ▲ +0.00%
Market Cap
$154.5M
Sector
Healthcare
Industry
Biotechnology
Beta
0.77
52-Wk Range
0.21-0.5821
CEO
Cheryl Maley
Country
AU
Currency
USD

Starpharma Holdings Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Richmond, VIC, AU. The stock last traded at $0.32, up 0.00% on the session, giving a market capitalisation of $154.5M. On trailing twelve-month figures it carries a trailing P/E of -24.56, a net margin of -62.0%. Its beta of 0.77 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-24.56
Price / Sales
16.83
Price / Book
13.17
EV / EBITDA
-10.51
Gross margin
86.3%
Operating margin
-159.6%
Net margin
-62.0%
Return on equity
—
Debt / equity
0.05
Current ratio
3.40
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
50
IPO date
2007-04-30
Headquarters
Richmond, VIC, AU
About Starpharma Holdings Limited

Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.

More research on SPHRF
SPHRF technical analysis SPHRF TheEdge Score Compare against peers
Open full interactive analysis & DCF →